Why Legend Biotech Corporation’s (LEGN) Stock Is Up 6.30%
As of Friday, August 21, Legend Biotech Corporation’s LEGN share price has surged by 6.30%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Commentary & Analysis
Which Is a Better Investment, Legend Biotech Corporation or Xencor, Inc. Stock?
Learn more about whether Legend Biotech Corporation or Xencor, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Why Legend Biotech Corporation’s (LEGN) Stock Is Down 5.11%
As of Wednesday, August 12, Legend Biotech Corporation’s LEGN share price has dipped by 5.11%, which has investors questioning if this is right time to buy.Jenna Brashear
What You Need to Know About Legend Biotech Corporation's Q3 Earnings
Legend Biotech Corporation's fiscal Q3 earnings report was released on Tuesday, August 11. Let's dive in to see if (LEGN) missed or beat analyst's expectations.Jenna Brashear
Why Legend Biotech Corporation’s (LEGN) Stock Is Up 6.49%
As of Tuesday, August 11, Legend Biotech Corporation’s LEGN share price has surged by 6.49%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | LEGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,121.5 | $286.3 | 64% |
|
| Shares Out (Mil) | 185.1 | 54.2 | 74% |
|
| Institutional Ownership | 99.8% | 92.8% | 94% |
|
| Float (Mil) | 90.3 | 39.7 | 59% |
|
| Beta | 0.39 | 0.94 | 22% |
|
| Avg Daily Volume (000s) | 2,708 | 534 | 86% |
|
| Price Change (52-week) |
(41.8%) | 58.7% | 18% |
|
| Growth | LEGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 68.8% | 13.6% | 97% |
|
| Net Income (5yr) | (2.2%) | (10.1%) | 37% |
|
| EPS (5yr) | 6.4% | 16.0% | 41 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 1.2% | (15.6%) | 65% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 2 | |
| Current EPS | $0.010 | ($0.010) | $1.080 | |
| Month Ago EPS | $0.100 | $0.302 | $1.098 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.100 | $0.280 | $1.335 | |
| Year/Year Chg | (103.3%) | (99.4%) | (209.6%) | |
| Financials | LEGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,139 | $37 | 52% |
|
| Net Income (TTM) (Mil) | ($250) | ($43) | 6% |
|
| EPS (TTM) | ($1.354) | ($1.400) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($82) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $205 | $2 | 84% |
|
| Long-Term Debt (Q1) (Mil) | $112 | $4 | 45% |
|
| Enterprise Value (Q1) (Mil) | $2,900 | $160 | 54% |
|
| Valuation | LEGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.08 | 2.77 | 73% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | LEGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 56.6% | 64.2% | 69% |
|
| Net Margin | (7.2%) | (75.9%) | 23% |
|
| ROA | (15.6%) | (47.3%) | 22% |
|
| ROE | (25.2%) | (55.0%) | 21% |
|
| Liabilities to Assets | 39.4% | 29.6% | 30% |
|
| F-Score | 3 | 2 | 18% |
|
Legend Biotech Corporation did not pass any screens on 8/20/2026.
